" /> IMMU-110 - CISMeF





Preferred Label : IMMU-110;

MeSH note : drug immunoconjugate composed of doxorubicin conjugated to the humanized anti-CD74 monoclonal antibody, hLL1, at a doxorubicin/monoclonal antibody ratio of approximately 8:1 (mol/mol); the excellent safety and efficacy profile of IMMU-110 supports clinical testing of this immunoconjugate in the treatment of CD74-positive B-cell malignancies;

Is substance : O;

Details


You can consult :


Nous contacter.
24/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.